On April 18th, President Trump signed an executive order intended to accelerate research of the medical use of psychedelics, including a call to the FDA to expedite consideration for those medicines that meet certain criteria. People are buzzing at the news, marking a shift in attitudes towards the use of psychedelics as a treatment for those suffering from major mental health issues like PTSD and treatment-resistant depression. So, what the heck does this mean moving forward?
For many in the field—like the people at the Multidisciplinary Association for Psychedelic Studies (MAPS)—there’s a sense of hopeful caution in the air. On one hand, we could be looking at a future where these promising therapies are available more quickly to those who need them most. That could mean more funding, fresh research, and guidelines grounded in real data, helping shape smarter policies and safer practices. Since each psychedelic works a bit differently, expanding the toolbox might give clinicians more ways to help their clients. Plus, as old stereotypes start to fade, there’s a chance these treatments will be appreciated as valid options for healing.
On the other hand, there are things to watch out for, too. If decisions are made too quickly, there’s a risk that patient safety could fall through the cracks or that psychedelic treatments might hit the market before we really know how well they work. There is the potential for the rush to overlook the importance of careful therapeutic support, which is key to the best outcomes. Without clear rules and guidance, those working in psychedelic research and clinical settings could be left to navigate many gray areas.
Most importantly, great care must be exercised when big business is knocking on the door. Some indigenous people have been stewards of these powerful medicines and they must be included in this unfolding process, including how to engage in wise harvesting practices. Otherwise, we risk repeating colonial patterns of cultural appropriation and biopiracy. It would be tragic to take something sacred, strip it from its context and people, and package it into just another product on the shelves.
So in a nutshell, the Executive Order bolsters ongoing efforts to research psychedelic medicines and promote accessibility and safety. At the same time, it will take wisdom, patience, and collaboration to continue the legacy of respect and stewardship.
___________________________________________